Novel antiplatelet therapies for treatment of patients with ischemic heart disease: Inhibitors of the platelet glycoprotein IIbIIIa integrin receptor

Frishman, William H.; Burns, Bryan; Atac, Bulent; Alturk, Najib; Altajar, Bassam; Lerrick, Kenneth

doi:10.1016/0002-8703(95)90091-8

Cited by 100 publications

(55 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In vitro aggregation has to be finely quantified for example in platelet aggregation to evaluate the effects of anti-aggregating drugs (4,6) and in chondrocyte condensation to study factors involved in chondrogenic differentiation (12).…”

Section: Discussionmentioning

confidence: 99%

Computer-based technique for cell aggregation analysis and cell aggregation in in vitro chondrogenesis

et al. 1997

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Computer-based technique for cell aggregation analysis and cell aggregation in in vitro chondrogenesis

et al. 1997

View full text Add to dashboard Cite

“…Several clinical trials demonstrated usefulness of this agent in patients with coronary artery disease undergoing balloon coronary angioplasty 32 and preliminary data sug -gest its potential use in acute ischemic stroke. 115 Abciximab may decrease thrombus formation and the combination with heparin did not add any antithrombotic effect to Abciximab alone.…”

Section: New a Pproaches In A Nti-aggregation T Herapymentioning

confidence: 99%

Coagulation and cancer: Implications for diagnosis and management

Loreto

Martinis

Corsi

et al. 2000

Pathol. Oncol. Res.

View full text Add to dashboard Cite

“…A better understanding of the processes involved in myocardial necrosis (MN) has stimulated the development of novel antiplatelet drugs which could play a vital role in the management of coronary artery diseases [6]. Although acetyl salicyclic acid (aspirin, ASA) is clearly the most efficacious antiplatelet agent in clinical use today [7], a large number of new drugs are being tested that may soon replace ASA therapy.…”

Section: Introductionmentioning

confidence: 99%

Antioxidant Potential of a Novel Tetrapeptide Derivative in Isoproterenol-Induced Myocardial Necrosis in Rats

Panchatcharam

Miriyala²,

Kumar³

et al. 2002

Pharmacology

View full text Add to dashboard Cite

A novel tetrapeptide derivative Boc-Lys(Boc)-Arg-Asp-Ser(tbu)-OtBu (PEP1261) has been tested in vivo in isoproterenol (ISO) hydrochloride (HCl)-induced myocardial necrosis in rats. ISO·HCl induces myocardial necrosis in rats which is accompanied by the distinct increase in heart weight, marked electrocardiographic changes, increase in the levels of serum marker enzymes and lipid peroxides and decrease in the levels of antioxidants. PEP1261 (5 mg/kg body weight i.p.) pre- and post-treatment effectively decreases serum marker enzyme levels, while the electrocardiographic changes get restored towards normalcy. PEP1261 also inhibits the action of the free radicals toxicity by increasing the levels of antioxidants and histological studies confirm the above findings. This study shows that PEP1261 could serve as an excellent cardioprotective agent possessing membrane-stabilizing action.

show abstract

Novel antiplatelet therapies for treatment of patients with ischemic heart disease: Inhibitors of the platelet glycoprotein IIbIIIa integrin receptor

Cited by 100 publications

References 48 publications

Computer-based technique for cell aggregation analysis and cell aggregation in in vitro chondrogenesis

Computer-based technique for cell aggregation analysis and cell aggregation in in vitro chondrogenesis

Coagulation and cancer: Implications for diagnosis and management

Antioxidant Potential of a Novel Tetrapeptide Derivative in Isoproterenol-Induced Myocardial Necrosis in Rats

Contact Info

Product

Resources

About